These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 37745141)

  • 1. The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice.
    Hysa E; Vojinovic T; Gotelli E; Alessandri E; Pizzorni C; Paolino S; Sulli A; Smith V; Cutolo M
    Reumatologia; 2023; 61(4):283-293. PubMed ID: 37745141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
    Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD007606. PubMed ID: 29630730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: A systematic review and meta-analysis.
    Hao Y; Oon S; Nikpour M
    Semin Arthritis Rheum; 2024 Aug; 67():152465. PubMed ID: 38796922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
    Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
    Cochrane Database Syst Rev; 2015 Dec; (12):CD007606. PubMed ID: 26666504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone chronotherapy.
    Spies CM; Cutolo M; Straub RH; Burmester GR; Buttgereit F
    Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S42-5. PubMed ID: 22018182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott IC; Kingsley GH; Scott DL
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.
    Kavanaugh A; Wells AF
    Rheumatology (Oxford); 2014 Oct; 53(10):1742-51. PubMed ID: 24729402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials.
    Palmowski A; Pankow A; Terziyska K; Nielsen SM; Christensen R; Bliddal H; Boyadzhieva Z; Buttgereit F
    Semin Arthritis Rheum; 2024 Feb; 64():152349. PubMed ID: 38100900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.
    Cutolo M; Spies CM; Buttgereit F; Paolino S; Pizzorni C
    Arthritis Res Ther; 2014 Nov; 16 Suppl 2(Suppl 2):S1. PubMed ID: 25608624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term effectiveness of RA-1 as a monotherapy and in combination with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis.
    Chopra A; Saluja M; Kianifard T; Chitre D; Venugopalan A
    J Ayurveda Integr Med; 2018; 9(3):201-208. PubMed ID: 29526468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.